Indeed, accumulating evidence from correlative observations as well as from functional analyses, in either clinical settings or in vitro studies8, 9, 10, 11, 12, now suggests that this is actually the case with glioblastoma, underscoring the absolute necessity for developing novel methods to inactivate MGMT in tumor cells to overcome TMZ resistance. This evidence concerns the gene MGMT and glioblastoma.